BRAF^(V600E)基因检测对良恶性甲状腺结节的诊断价值  

Value of BRAF^(V600E) Genetic Testing for Diagnosis of Benign and Malignant Thyroid Nodules

作　　者：钱伟明[1] 姜协[1] 邵荣[1] 薛剑[2] 王鹏[1] 

机构地区：[1]江苏省常州市武进中医医院,江苏武进213003 [2]军事医学科学院附属医院,北京100071

出　　处：《生物技术通讯》2017年第2期123-127,共5页Letters in Biotechnology

摘　　要：目的:探讨BRAF^(V600E)基因检测在甲状腺结节中的诊断价值,评估其诊断良恶性甲状腺结节的应用价值。方法:选取2015年1~12月江苏省常州市武进中医医院收治的甲状腺结节患者,入院后测定BRAF^(V600E)基因表型,采用细针穿刺细胞学(FNAC)检测其性质,采用手术组织病理学对患者甲状腺结节进行良恶性鉴别,分析BRAF^(V600E)基因与良恶性结节的相关性,评估其对于甲状腺结节良恶性鉴别的指导价值。结果:共入组甲状腺结节患者92例,其中恶性65例;多因素分析表明BRAF^(V600E)基因突变与恶性甲状腺结节呈相关性(P<0.01),OR为44.42(95%CI:5.66~348.44);BRAF^(V600E)基因突变预测其恶性甲状腺结节发生的敏感性和特异性分别为63%(95%CI:0.50~0.74)和96%(95%CI:0.79~0.99)。结论:BRAF^(V600E)突变与甲状腺癌的发生有显著的相关性,其能显著提高良恶性甲状腺结节的检出率。Objective： To evaluate the diagnostic value of the BRAF^V600E genetic testing in thyroid nodules and assess its value diagnosis combined with fine-needle aspiration cytology（FNAC） of benign and malignant thyroid nodules used in clinical. Methods： We enrolled the thyroid nodules patients treated in Wujin Chinese Medicine Hospital from January to December 2015. We determinated the BRAF^V600E phenotype and FNAC after admission, using the surgical histopathology performed on patients with benign and malignant thyroid nodules. Results： A total of 92 thyroid nodules patients were enrolled, including 65 cases of malignant nodules. Multivariate results showed that the mutation of BRAFTM and malignant thyroid nodules were correlated, the risk increased 44.42 times（OR= 44.42, 95% CI： 5.66-348.44）. The mutation of BRAF^V600E predicts the occurrence of malignant thyroid nodules sen- sitivity and specificity were 63%（95% CI： 0.50-0.74） and 96%（95% CI： 0.79-0.99）. Conclusion： The mutation of BRAF^V600E, which can significantly improve the detection of benign and malignant thyroid nodules rate incidence of thyroid cancer has a significant correlation with the incidence of thyroid cancer.

关 键 词：BRAF^V600E基因 甲状腺结节 诊断价值 

分 类 号：R446[医药卫生—诊断学] Q789[医药卫生—临床医学]